MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.
Business & FinanceDealsHealth
MoonLake Immunotherapeutics explores sale
14 July 2023, 5:43 pm 1 minute
MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday, giving the company a market value of $3.3 billion.
Topics of Interest: Business & FinanceDealsHealth
Type: Reuters Best
Sectors: Business & FinancePharmaceuticals & Healthcare
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Significant National Story
More of Reuters Best
September 04, 2023
August 28, 2023